Enliven (ELVN) news
Recent news
Enliven Therapeutics appoints Kristine Ball to board of directors ahead of planned phase 3 trial initiation this year
Enliven Therapeutics, Inc. (NASDAQ:ELVN) has announced the appointment of Kristine Ball to its board of directors, a move expected to support the company as it prepares to initiate a Phase 3 trial for its lead candidate, ELVN-001, in the current fiscal year. Ball brings extensive leadership and…
AInvest Wire · 16h agoEnliven Therapeutics, Inc.: JP Morgan initiates coverage with overweight rating; target price $75
JPMorgan Chase & Co. has initiated coverage on Enliven Therapeutics, Inc. (NASDAQ: ELVN) with an "overweight" rating and a target price of $75 per share, signaling confidence in the company’s growth potential. The move comes amid recent developments, including the company’s presentation at the…
AInvest Wire · Oct 1, 2026Enlivens Therapeutics, Inc.: H.C. Wainwright raises target price to $64 from $56
Enliven Therapeutics, Inc. (NASDAQ:ELVN) has seen recent upward revisions to its price targets from key analysts, reflecting growing confidence in its pipeline and market potential. On March 26, H.C. Wainwright raised its price target for the stock from $48 to $56, maintaining its Buy rating. This…
AInvest Wire · Jul 9, 2026Enlivens Therapeutics closes upsized stock offering
Enliven Therapeutics (Nasdaq: ELVN) has completed its upsized public offering, raising approximately $400.0 million in gross proceeds before underwriting discounts and other expenses. The offering included the sale of 8,933,334 shares of common stock at $37.50 per share and pre-funded warrants to…
AInvest Wire · Jun 15, 2026Enliven prices upsized share offering at $37.50/shr
Enliven Therapeutics, Inc. (Nasdaq: ELVN) has priced its public offering of 8,394,737 shares of common stock at $19.66 per share, with option for pre-funded warrants . The offering, which includes pre-funded warrants to purchase up to 1,780,263 shares at $19.659 per warrant, is expected to generate…
AInvest Wire · Jun 12, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.